NOT FOR HUMAN CONSUMPTION

NSI-189 is an orally bioavailable, benzylpiperazine-aminopyridine small molecule originally developed to stimulate hippocampal neurogenesis and improve mood and cognition. It is not approved by any regulator. After Phase 1 safety and signal-finding studies in major depressive disorder (MDD), a Phase 2 program did not meet its primary endpoint; development has largely stalled. Preclinical data indicate pro-neurogenic, synaptogenic, and neurotrophic effects in hippocampus with downstream impacts on stress circuitry and cognition.

Additional Benefits of NSI-189 Now Under Investigation

Benefit	Key take-aways
1 Hippocampal neurogenesis	In vitro and rodent studies show proliferation/differentiation of hippocampal precursors and spine density increases; memory behaviors improve in stress/lesion models. Stem Cell Reports; Journal of Neuroscience
2 Antidepressant signal (MDD)	Early Phase 1b showed exploratory improvements on depression scales; the Phase 2RCT failed its primary endpoint but suggested subset/time-course signals, insufficient for approval. Molecular Psychiatry; Depression & Anxiety
3 Cognitive enhancement (processing speed/working memory)	Rodent data and small human exploratory tasks suggested modest cognitive benefits, especially in processing speed and verbal learning domains. Neuropsychopharmacology; CNS Drugs
4 Anhedonia & motivation	Preclinical stress paradigms show sucrose preference and effort-based tasksimprovements consistent with mesolimbic normalization. Biological Psychiatry; Translational Psychiatry
5 Neuroprotection after ischemia/TBI	In stroke/TBI models, NSI-189 reduced lesion-associated behavioral deficits and supported neurite/synapse recovery. Brain Research; Experimental Neurology
6 Anti-inflammatory/neuroimmune modulation	Down-shift of microglial NF-κB and cytokines (IL-1β, TNF-α) reported alongside neurogenesis; causal links remain exploratory. Glia; Journal of Neuroinflammation
7 Stress-axis normalization	Rodent work shows HPA-axis re-tuning with lower corticosterone reactivity and improved hippocampal feedback. Endocrinology; Psychoneuroendocrinology
8 Neuroplasticity in aging	Signals for hippocampal volume preservation and memory tasks in aged rodents; human aging data absent. Aging Cell; Neurobiology of Aging
9 Adjunct in PTSD/cognitive syndromes	Concept: pair neurogenesis with psychotherapy/rehab to consolidate learning; only preclinical or hypothesis-driven studies so far. Frontiers in Psychiatry; Behavioural Brain Research

2. Molecular Mechanism of Action

2.1 Pharmacodynamics (working model)

Neurogenesis & synaptogenesis: Up-regulates BDNF, CREB, MAPK/ERK, and PI3K–Akt–mTOR pathways → progenitor proliferation, dendritic spine formation, and synaptic proteins (PSD-95, synapsin).
Neuroimmune & HPA modulation: Restraint of NF-κB signaling and improved glucocorticoid feedback in hippocampus → stress resilience.
Not a monoaminergic reuptake inhibitor/MAOI. Any serotonergic/dopaminergic effects appear downstream of plasticity cascades.

2.2 Down-stream biology

Pathway	Functional outcome	Context
BDNF–TrkB → ERK/CREB	Plasticity gene induction, mood/cognition	Hippocampus
PI3K–Akt–mTOR	Cell survival, dendritic growth	Hippo/cortex
NF-κB restraint	↓ Pro-inflammatory cytokines	Microglia
HPA re-tuning	Stress reactivity ↓	Limbic loop

3. Pharmacokinetics

Route: Oral (phosphate salt).
Brain penetration: Demonstrated in animals; human CNS levels not published.
Half-life/steady state: Hours to low-teens half-life reported; once- or twice-daily regimens used in trials.
Metabolism: Hepatic oxidative pathways (exact CYP liabilities not fully characterized).
Food effect/interactions: Limited public data; not a classic CYP inducer/inhibitor.

4. Clinical Evidence (high-level)

Phase 1b in MDD: Generally well tolerated; exploratory antidepressant and cognitive signals across several scales.
Phase 2 in MDD: Did not meet primary endpoint vs placebo; some secondary/exploratory outcomes hinted at benefit in subgroups/time windows, insufficient for advancement.
Imaging/biomarkers: Small datasets explored hippocampal volumetrics and peripheral BDNF, inconclusive.

Evidence quality note: Strong preclinical plausibility with neurogenesis/circuit biology; human efficacy unproven after a negative Phase 2. Any clinical use should be confined to research settings.

5. Emerging Clinical Interests (conceptual)

Field	Rationale	Status
Treatment-resistant depression	Plasticity beyond monoamines	Concept
Post-stroke/TBI cognitive rehab	Pairing synaptogenesis with therapy	Preclinical/early concept
PTSD	Extinction learning support	Concept
Age-related cognitive decline	Hippocampal neurogenesis	Preclinical concept

6. Safety and Tolerability

Common AEs in trials: Headache, dizziness, somnolence/insomnia, nausea, fatigue, generally mild to moderate.
Vitals/labs/ECG: No consistent safety signal in short-term studies.
Neuropsychiatric: Activation/insomnia in a subset; monitor for anxiety or agitation early in dosing.
Suicidality monitoring: Standard for antidepressant investigations, no clear excess signal reported, but vigilance required.
Long-term safety: Unknown (no lengthy exposure datasets).
Drug interactions: Limited data; because the MOA is non-monoaminergic, risk of serotonin syndrome appears low when combined with SSRIs/SNRIs, but combination evidence is sparse, use caution in research settings.

Comparative snapshot (neuroplasticity-oriented antidepressants)

Feature	NSI-189	Ketamine/Esketamine	SSRIs/SNRIs
Primary action	Neurogenesis/BDNF–CREB (putative)	Rapid glutamatergic plasticity	Monoamine transport
Onset	Gradual (weeks)	Rapid (hours–days)	Weeks
Evidence	Negative Phase 2 primary	Robust TRD efficacy	Robust MDD efficacy
Abuse liability	Low (expected)	Moderate (controlled)	Low

7. Regulatory Landscape

Not approved (no active late-stage programs publicly ongoing).
Any availability is via research channels; consumer “nootropic” products are unregulated and may be misidentified, avoid outside formal trials.

8. Practical Take & Future Directions

Current stance: NSI-189 remains experimental with insufficient clinical efficacy.
If pursued scientifically: Target biotype-enriched populations (low hippocampal volume, high inflammation, high anhedonia), use adaptive trial designs, and anchor outcomes with objective cognition, digital phenotyping, and MRI/EEG biomarkers.
Combination hypotheses: Pair with psychotherapy/rehab, exercise, or sleep-based plasticity protocols to exploit a pro-neurogenic state.
Translational needs: Clear target engagement biomarkers, refined PK/PD, and longer blinded trials in precisely defined cohorts.

Selected References

Stem Cell Reports; Journal of Neuroscience, NSI-189-driven neurogenesis and synaptogenesis in vitro/in vivo.
Molecular Psychiatry; Depression & Anxiety; CNS Drugs, Phase 1/2 clinical results in MDD (safety, exploratory signals, Phase 2 miss).
Neuropsychopharmacology; Translational Psychiatry, Plasticity markers, cognition, and stress-model outcomes.
Glia; Journal of Neuroinflammation, Neuroimmune modulation accompanying neurogenesis.
Endocrinology; Psychoneuroendocrinology, HPA-axis changes linked to hippocampal plasticity.
Brain Research; Experimental Neurology, Post-stroke/TBI recovery paradigms.

NSI-189 100x30mg

Complete the setup